• Recruiting

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor MM

Updated: May 23

NCT04850846: Phase 2: Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma


metformin

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma


The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multiple myeloma.


The names of the study drug involved in this study is:

Metformin, extended release

Placebo (a pill that has no active ingredients)


Sponsor:

Dana-Farber Cancer Institute


Collaborator:

National Cancer Institute (NCI)

 

ClinicalTrials.gov Identifier: NCT04850846


Official Title: A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma


First Posted: April 20, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: Metformin XR

Other: Placebo

 

Locations


United States, Massachusetts

United States, New Hampshire



Posts Archive